CALLICUTT JACK W

Average Profitability
<0.0001%
Insider Buys Quantity
4
Insider Buys Sum
$27,695.12
Insider Sells Quantity
7
Insider Sells Sum
$2.96M

Insider Activity of CALLICUTT JACK W

The largest purchase of all time was on 2019-05-31 and amounted to 2354 shares of Galectin Therapeutics Inc. for $10,075.

The largest sale of all time was on 2018-06-19 and amounted to 128733 shares of Galectin Therapeutics Inc. for $1.16M.

Biography of CALLICUTT JACK W

No biography is available at this moment.

2022-11-17PurchaseGalectin Therapeutics Inc.
GALT
Chief Financial Officer
4,000
0.0065%
$1.32$5,280+22.79%
2019-05-31PurchaseGalectin Therapeutics Inc.
GALT
Chief Financial Officer
2,354
0.005%
$4.28$10,075-23.33%
2018-06-20SaleGalectin Therapeutics Inc.
GALT
Chief Financial Officer
97,267
0.2583%
$8.08$786,034-39.57%
2018-06-19SaleGalectin Therapeutics Inc.
GALT
Chief Financial Officer
128,733
0.339%
$9.01$1.16M-46.15%
2018-06-12SaleGalectin Therapeutics Inc.
GALT
Chief Financial Officer
9,294
0.0269%
$7.01$65,167-23.38%
2018-06-11SaleGalectin Therapeutics Inc.
GALT
Chief Financial Officer
20,000
0.0558%
$6.38$127,500-18.9%
2018-06-08SaleGalectin Therapeutics Inc.
GALT
Chief Financial Officer
100,000
0.2438%
$5.75$575,000-20.99%
2018-05-31SaleGalectin Therapeutics Inc.
GALT
Chief Financial Officer
46,651
0.1201%
$5.00$233,255-3.74%
2018-04-04SaleGalectin Therapeutics Inc.
GALT
Chief Financial Officer
3,349
0.0092%
$5.00$16,745+3.16%
2014-08-14PurchaseGalectin Therapeutics Inc.
GALT
Chief Financial Officer
2,000
0.0089%
$4.54$9,090-23.43%
2013-11-19PurchaseGalectin Therapeutics Inc.
GALT
Chief Financial Officer
520
0.0029%
$6.25$3,250+66.72%
Company
About Prismo.proPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.